European Commission grants marketing authorisation for subcutaneous formulation of daratumumab for the treatment of multiple myeloma

This product, approved for all existing indications of the IV formulation, is administered as a fixed-dose over approximately 3-5 minutes. Approval was based on data from a Phase III study, demonstrating non-inferiority to the IV formulation.


Biospace Inc.